Company-wide revenue
Reported revenue in 2021 ¥272.94B Reported revenue in 2025 ¥247.36B
- growth amount
- −¥25.58B
- growth annualized
- -2.4%
- growth total
- -9.4%
Japanese company profile · 4544
H.U. Group Holdings, Inc.
In its FY2025 public filing, H.U. Group Holdings, Inc. reports Inspection and related services, Clinical testing drugs, Healthcare services. The page shows business-level revenue and profit where the source disclosures support comparison.
Original Japanese company name: Ｈ．Ｕ．グループホールディングス株式会社
English company name recorded in Japan's EDINET filer data. English company name source
Reported company-wide figures
What does this company do?
What does this company do?
H.U. Group Holdings, Inc.'s largest reported business by revenue in FY2025 was Inspection and related services.
The business with the highest reported segment profit in FY2025 was Clinical testing drugs.
FY2025 · fiscal year ended March 2026 View original filing ↗ The source document may be in Japanese.
Business structure
How does it make money?
| Business | Sales | Revenue share | Operating profit |
|---|---|---|---|
| Inspection and related services | ¥157.6B ↗ | 63.7% | ¥31M ↗ |
| Clinical testing drugs | ¥64.99B ↗ | 26.3% | ¥9.05B ↗ |
| Healthcare services | ¥29.45B ↗ | 11.9% | ¥1.76B ↗ |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended March 2026. Revenue and profit are shown only where the filing and data support a comparison.
Original Japanese label
- Inspection and related services
- 検査・関連サービス事業
- Clinical testing drugs
- 臨床検査薬事業
- Healthcare services
- ヘルスケア関連サービス事業
- Sales
- 売上高
- Operating profit
- 営業利益
Original Japanese label
- Inspection and related services
- 検査・関連サービス事業
- Clinical testing drugs
- 臨床検査薬事業
- Healthcare services
- ヘルスケア関連サービス事業
- Sales
- 売上高
- Operating profit
- 営業利益
Reported Sales by business over time
Reported Sales by business over time
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Inspection and related services | ¥180.24B | ¥163.39B | ¥146.99B | ¥153.49B | ¥157.6B |
| Clinical testing drugs | ¥74.17B | ¥77.67B | ¥67.52B | ¥64.97B | ¥64.99B |
| Healthcare services | ¥28.7B | ¥27.77B | ¥28.32B | ¥29.57B | ¥29.45B |
All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.
What is growing?
What is growing?
Business revenue growth
Healthcare services
Reported revenue in 2021 ¥28.7B Reported revenue in 2025 ¥29.45B
- growth amount
- +¥754M
- growth annualized
- +0.7%
- growth total
- +2.6%
View original filing
Healthcare services
Reported profit margin in 2022 +3.8%
Reported profit margin in 2025 +6.0%
- growth margin points
- +2.2
View original filing
This describes a reported period; it is not a forecast.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
Public filing
FY2025 · fiscal year ended March 2026
The source document may be in Japanese.
Filing ID: S100YB46
View original filing ↗Ask about this company
Ask about this company
The source document may be in Japanese.